Changes in plasma amino acids after electroconvulsive therapy of depressed patients
Introduction
The neurobiological action of electroconvulsive therapy (ECT) is not fully understood, but it is known that ECT has effects on several neurotransmitters and their receptors, neuropeptides, hormones and neurotrophic factors (Wahlund and von Rosen, 2003). ECT is widely used and regarded as safe and effective in major depressive disorders and some other psychiatric syndromes such as catatonia and mania (American Psychiatric Association, 1990).
Several experimental and human studies indicate a role for the amino acid transmitters gamma-aminobutyric acid (GABA) and glutamate in the pathogenesis of mood disorders, especially depression; for reviews, see Krystal et al. (2002), Brambilla et al. (2003), and Tunnicliff and Malatynska (2003). In humans, reduced concentrations of GABA both in plasma and in cerebrospinal fluid (CSF) have been reported in depressed patients (Brambilla et al., 2003, Tunnicliff and Malatynska, 2003). Furthermore, decreased cortical GABA concentrations, demonstrated by proton magnetic resonance spectroscopy (MRS), have been associated with major depression (Sanacora et al., 1999, Sanacora et al., 2004). Alterations in the plasma levels of glutamate as well as those of aspartate, serine, glycine and taurine, have been observed in major depression (Altamura et al., 1993, Altamura et al., 1995, Maes et al., 1998). A higher plasma serine concentration has been considered a possible marker for depression, but also for schizophrenia, paranoia and mania (Waziri et al., 1984, Maes et al., 1995, Sumiyoshi et al., 2004). Altered ratios of plasma levels of serine and glycine have been found in patients suffering from major depression, but also in subjects with schizophrenia (Altamura et al., 1995, Sumiyoshi et al., 2004). Recently, Sanacora et al. (2004) reported increased cortical concentrations of glutamate in depressed subjects.
GABA and glutamate may thus be targets of treatment of depression with drugs and ECT (Krystal et al., 2002, Brambilla et al., 2003, Ketter and Wang, 2003, Pfleiderer et al., 2003). The increase in occipital cortex GABA concentrations following ECT suggests possible GABAergic involvement in the positive actions of ECT (Sanacora et al., 2003). On the other hand, plasma GABA has been reduced after ECT for at least 1 h (Devanand et al., 1995). Reduced cortical glutamate/glutamine (Glx) levels have been measured in depressed patients. Glx concentrations have also correlated negatively with severity of depression. After successful treatment with ECT, Glx increased significantly in the amygdalar region, in the dorsolateral prefrontal cortex and in the left anterior cingulum (Pfleiderer et al., 2003, Michael et al., 2003a, Michael et al., 2003b). However, data are scant on the effects of different treatments, especially those of ECT, on the plasma levels of these and other amino acids in patients with depression.
The purpose of this study was to measure the acute effects of a single administration of ECT on the plasma levels of amino acids in depressed patients. Altogether 23 plasma amino acids were analyzed before and up to 48 h after ECT.
Section snippets
Methods
The study was performed at the Department of Psychiatry, Tampere University Hospital, Finland. We included 10 patients, seven women and three men, with a mean age of 55.6 years (range 28–70 years). All the patients fulfilled the diagnostic criteria of DSM-IV major depressive disorder (MDD) (American Psychiatric Association, 1994); four of them showed psychotic features. The patients had no other medical or neurological disorders except for one patient (no. 7), who had ischemic heart disease and
ECT procedure
ECT was administered with a Thymatron DGx (Somatics, Inc.) brief-pulse device. The initial stimulus dosage (millicoulombs) was adjusted to all patients with the age method being about five times their age (Swartz and Abrams, 1996). All patients were treated with bilateral ECT. Anesthesia was induced with propofol (5 patients) or methohexital (5 patients) and muscle relaxation with succinylcholine. The initial dosage was 1.5 mg/kg of propofol or 1 mg/kg of methohexital and 0.5 mg/kg of
Blood sampling and biochemical analyses
The plasma samples were collected before ECT and at 2, 6, 24, and 48 h after the treatment. The samples were centrifuged at 3000 rpm for 10 min and stored at − 70 °C before the analyses. Altogether 23 plasma amino acids were analyzed, namely alanine, amino-n-butyrate, arginine, asparagine, aspartate, citrulline, GABA, glutamate, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, ornithine, phenylalanine, serine, taurine, threonine, tryptophan, tyrosine and valine. The plasma
Statistical methods
The mean values and standard deviations were calculated for continuous variables. Statistical significance of changes between different time points was tested by paired samples t-test. All analyses were performed using a microcomputer and the Statistica/WIN package (version 5.1; Statsoft Inc., Tulsa, OK). A P value of less than 0.05 was considered statistically significant.
Results
The mean plasma concentrations at baseline and the mean changes after ECT of all amino acids are shown in Table 2. Statistically significant elevations in the plasma levels of alanine, asparagine, aspartate, glutamate, glycine, histidine, isoleucine, leucine, lysine, methionine, ornithine, phenylalanine, serine, threonine, tryptophan, tyrosine and valine were observed. The glutamine and taurine levels did not show statistically significant changes. The levels of GABA were decreased at 2 h
Discussion
To the best of our knowledge, the present study is the first to analyze the acute effect of ECT on the whole spectrum of plasma amino acids. We showed that ECT increased the plasma levels of most amino acids but decreased those of GABA. There were indications of varying kinetics in the ECT-induced changes of different amino acids.
To date, only plasma levels of GABA, tryptophan and some other amino acids in association with ECT have been studied (Devanand et al., 1995, Mokhtar et al., 1997,
Acknowledgments
The support of the Maire Taponen Foundation is gratefully acknowledged.
References (43)
- et al.
Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study
Biological Psychiatry
(2000) - et al.
The specificity of platelet glutamate receptor supersensitivity in psychotic disorders
Life Sciences
(2000) - et al.
Effect of electroconvulsive therapy on biopterin and large neutral amino acids in severe, medication-resistant depression
Psychiatry Research
(2001) - et al.
No early effects of electroconvulsive therapy on tryptophan metabolism and disposition in endogenous depression
Biological Psychiatry
(1997) - et al.
Effective electroconvulsive therapy reverses glutamate/glutamine deficit in the left anterior cingulum of unipolar depressed patients
Psychiatry Research: Neuroimaging
(2003) - et al.
Serine metabolism and psychosis
Psychiatry Research
(1984) - et al.
Plasma concentrations of excitatory amino acids, serine, glycine, taurine and histidine in major depression
European Neuropsychopharmacology
(1995) - et al.
Plasma and platelet excitatory amino acids in psychiatric disorders
American Journal of Psychiatry
(1993) Task Force Report
Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training and Privileging
(1990)Diagnostic and Statistical Manual of Mental Disorders
(1994)
Normal PET after long-term ECT
American Journal of Psychiatry
Electroconvulsive therapy and cerebral computed tomography
Acta Psychiatrica Scandinavica
Platelet glutamate receptor supersensitivity in major depressive disorder
Clinical Neuropharmacology
GABAergic dysfunction in mood disorders
Molecular Psychiatry
Disorientation and bilateral moderately suprathreshold titrated ECT
Convulsive Therapy
Neuroexcitatory amino acids and their relation to infarct size and neurological deficit in ischemic stroke
Stroke
A glutamatergic model of ECT-induced memory dysfunction
Harvard Review of Psychiatry
Brain anatomic effects of electroconvulsive therapy. A prospective magnetic resonance imaging study
Archives of General Psychiatry
Does ECT alter brain structure?
American Journal of Psychiatry
Effects of electroconvulsive therapy on plasma GABA
Convulsive Therapy
The hippocampus in patients treated with electroconvulsive therapy: a proton magnetic spectroscopic imaging study
Archives of General Psychiatry
Cited by (40)
Tryptophan metabolite concentrations in depressed patients before and after electroconvulsive therapy
2020, Brain, Behavior, and ImmunityCitation Excerpt :A handful of studies have investigated the impact of ECT on TRP concentrations in blood. However, most of these assessed the acute effects of a single ECT treatment, which is unlikely to be associated with a substantial therapeutic response (Hoekstra et al., 2001; Palmio et al., 2005). Our results are broadly consistent with outcomes from the limited number of studies to date assessing the effects of ECT on KP metabolites (Aarsland et al., 2019; Guloksuz et al., 2015).
The impact of electroconvulsive therapy on the tryptophan-kynurenine metabolic pathway
2015, Brain, Behavior, and ImmunityEffects of electroconvulsive therapy on neural complexity in patients with depression: Report of three cases
2013, Journal of Affective DisordersTaurine and glutathione levels in plasma before and after ECT treatment
2012, Psychiatry ResearchCitation Excerpt :However, alterations in taurine and GSH levels are less well studied. In a previous report, Palmio et al. (2005) found no immediate effect on plasma taurine levels during the first 24 h after a single administration of ECT. Because several ECT treatments are required to induce an anti-depressive effect, we designed this study to examine the effect that followed a series of administrations.
Safety and efficacy of electroconvulsive therapy for the treatment of agitation and aggression in patients with dementia
2012, American Journal of Geriatric PsychiatryCitation Excerpt :The data regarding ECT effects on GABA more consistently support an enhancement of GABAergic neurotransmission and inhibition.43 ECT also seems to enhance norepinephrine,44 glutamatergic45 and dopaminergic neurotransmission.46 Enhanced GABAergic neurotransmission may partially explain the mechanism of action of ECT in dementia patients with agitation and aggression.